Shanghai MicroPort MedBot (Group) Co., Ltd. Announces Completion of H Share Full Circulation

Key Highlights for Investors

• Completion of H Share Full Circulation: The board of Shanghai MicroPort MedBot (Group) Co., Ltd. has officially announced the completion of its H share full circulation program. This process involved the conversion of an aggregate of 5,989,798 unlisted shares into H shares, which was finalized on 23 April 2026.
• Commencement of Trading: The newly converted H shares will begin trading on The Stock Exchange of Hong Kong Limited at 9:00 a.m. on 24 April 2026.
• Regulatory Approvals: This follows prior notifications and approvals from the China Securities Regulatory Commission and the Stock Exchange of Hong Kong, confirming compliance with all necessary requirements for the share conversion and listing.

Detailed Shareholding Structure Before and After Conversion

The conversion significantly alters the shareholding structure of the company. Here is a breakdown of the numbers:

This conversion further increases the liquidity of the Company’s H shares in the public market and significantly reduces the proportion of unlisted shares.

Potential Impact on Share Price

• Increased Liquidity: The conversion of nearly 6 million unlisted shares into H shares and their subsequent listing increases the free float of the company’s shares on the Hong Kong market. This could attract more attention from institutional and retail investors, potentially leading to increased trading activity.
• Market Perception: The move to full H share circulation is often seen as a positive step toward greater transparency and improved corporate governance, which may enhance investor confidence.
• Potential Price Volatility: With the sudden increase in tradable shares, there is potential for increased price volatility around the listing date as the market absorbs the additional supply.

Important Notes for Shareholders

• Exercise Caution: The company has advised shareholders and potential investors to exercise caution when trading its shares, particularly around the commencement of trading for the converted H shares.
• Board Composition: Investors should note the company’s current board structure, which includes a mix of executive, non-executive, and independent non-executive directors, with Dr. Zhaohua Chang serving as Chairman.

Conclusion

The completion of the H share full circulation marks a significant milestone for Shanghai MicroPort MedBot (Group) Co., Ltd., aligning it further with international capital markets and potentially impacting the company’s share price due to increased liquidity and investor interest. Investors should monitor the stock closely for possible short-term volatility and consider the long-term implications of a more accessible share structure.

Disclaimer: The above information is provided for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research or consult with a qualified financial adviser before making any investment decisions. Shanghai MicroPort MedBot (Group) Co., Ltd. and its board accept no responsibility for any loss arising from reliance on this information.

View MEDBOT-B Historical chart here